Tetraphase Pharmaceuticals (TTPH) Rating Increased to Hold at Zacks Investment Research
Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from a sell rating to a hold rating in a research report report published on Friday.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Several other brokerages have also recently weighed in on TTPH. BMO Capital Markets increased their target price on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an outperform rating in a report on Wednesday, October 4th. Needham & Company LLC restated a hold rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. HC Wainwright increased their target price on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the company a buy rating in a report on Monday, November 6th. Finally, ValuEngine cut Tetraphase Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $15.15.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). The company had revenue of $4.10 million during the quarter, compared to analysts’ expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. Tetraphase Pharmaceuticals’s quarterly revenue was up 355.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.58) EPS. equities analysts expect that Tetraphase Pharmaceuticals will post -2.88 EPS for the current fiscal year.
In other Tetraphase Pharmaceuticals news, Director L Patrick Gage purchased 3,880 shares of the stock in a transaction on Wednesday, November 29th. The stock was acquired at an average price of $6.45 per share, with a total value of $25,026.00. Following the transaction, the director now directly owns 38,880 shares of the company’s stock, valued at approximately $250,776. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total value of $44,507.07. The disclosure for this sale can be found here. Corporate insiders own 5.50% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in TTPH. SG Americas Securities LLC bought a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter worth approximately $107,000. Brighton Jones LLC bought a new position in shares of Tetraphase Pharmaceuticals in the 3rd quarter worth approximately $108,000. AXA bought a new position in shares of Tetraphase Pharmaceuticals in the 2nd quarter worth approximately $132,000. Voya Investment Management LLC raised its position in shares of Tetraphase Pharmaceuticals by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 3,104 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new position in shares of Tetraphase Pharmaceuticals in the 2nd quarter worth approximately $147,000. 58.15% of the stock is owned by institutional investors and hedge funds.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.